TY - JOUR
T1 - Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India
AU - Saravanan, Shanmugam
AU - Madhavan, Vidya
AU - Balakrishnan, Pachamuthu
AU - Smith, Davey M.
AU - Solomon, Sunil Suhas
AU - Sivamalar, Sathasivam
AU - Poongulali, Selvamuthu
AU - Kumarasamy, Nagalingeswaran
AU - Schooley, Robert T.
AU - Solomon, Suniti
AU - Kantor, Rami
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-Associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
AB - Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-Associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
UR - http://www.scopus.com/inward/record.url?scp=84874475855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874475855&partnerID=8YFLogxK
U2 - 10.1089/aid.2011.0334
DO - 10.1089/aid.2011.0334
M3 - Article
C2 - 23045961
AN - SCOPUS:84874475855
SN - 0889-2229
VL - 29
SP - 630
EP - 632
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 3
ER -